jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Sjogren's Syndrome Profile

Blood

2 parameters

image

Report in 96Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Autoimmune antibody panel.

₹3,999₹5,679

30% OFF

Parameters

  • List of Tests
    • Anti-ro SSA-IgG Anitbodies by EIA
    • Anti-la SSB-IgG Antibodies by EIA

Sjogren's Syndrome Profile

  • Why is it done?
    • This test package detects autoantibodies associated with Sjogren's syndrome, a chronic autoimmune disorder affecting salivary and lacrimal glands
    • Anti-Ro SSA-IgG antibodies and Anti-La SSB-IgG antibodies are the two primary serological markers used to confirm diagnosis of Sjogren's syndrome
    • Ordered when patients present with symptoms of xerostomia (dry mouth) and xerophthalmia (dry eyes) that persist for more than 3 months
    • Used to differentiate Sjogren's syndrome from other autoimmune conditions and to assess disease activity and severity
    • Anti-La SSB-IgG is more specific for Sjogren's syndrome, typically occurring in approximately 40-60% of patients, while Anti-Ro SSA-IgG is present in 40-60% of cases
    • The two tests work together: Anti-La SSB-IgG is nearly always found alongside Anti-Ro SSA-IgG, but Anti-Ro SSA-IgG can occur independently
    • Recommended as part of the classification criteria for diagnosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines
  • Normal Range
    • Anti-Ro SSA-IgG Antibodies by EIA: Negative or <1.0 IU/mL (or <0.1-1.0 index units depending on laboratory); values below the cutoff indicate absence of antibodies
    • Anti-La SSB-IgG Antibodies by EIA: Negative or <1.0 IU/mL (or <0.1-1.0 index units depending on laboratory); values below the cutoff indicate absence of antibodies
    • Both tests are typically reported as negative/positive or as numerical values with a specific cutoff threshold; exact reference ranges may vary by laboratory and assay methodology
    • Negative result: Suggests absence of these specific autoantibodies; does not completely rule out Sjogren's syndrome as seronegative cases exist (10-30% of patients)
    • Positive result: Indicates presence of autoantibodies; combination of both positive tests is highly specific for Sjogren's syndrome diagnosis
  • Interpretation
    • Anti-Ro SSA-IgG Negative + Anti-La SSB-IgG Negative: Sjogren's syndrome less likely; consider other autoimmune conditions or seronegative Sjogren's syndrome with additional clinical and histopathological confirmation needed
    • Anti-Ro SSA-IgG Positive + Anti-La SSB-IgG Negative: Consistent with Sjogren's syndrome; Anti-Ro without Anti-La occurs in approximately 10-15% of seropositive patients and indicates disease but not always the complete antibody profile
    • Anti-Ro SSA-IgG Positive + Anti-La SSB-IgG Positive: Highly specific for primary Sjogren's syndrome; this combination has approximately 97% specificity for the disease diagnosis
    • Anti-La SSB-IgG without Anti-Ro SSA-IgG: Extremely rare pattern; Anti-La is virtually never found alone and warrants verification or repeat testing as it almost always co-occurs with Anti-Ro SSA-IgG
    • Elevated antibody titers correlate with disease severity but do not always predict symptom progression or remission in individual patients
    • False positives may occur in other autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and polymyositis; clinical correlation is essential
    • Antibodies may be detected before symptom onset; positive results in asymptomatic individuals warrant monitoring and patient education about symptom awareness
    • Patients may have variable antibody levels over time; however, seroconversion (negative to positive) is uncommon, and seronegativity (remaining negative) typically persists throughout disease course
  • Associated Organs
    • Anti-Ro SSA-IgG Antibodies: Primarily affect exocrine glands (salivary and lacrimal glands) causing glandular destruction and dysfunction; IgG antibodies target 52-kDa and 60-kDa Ro52 and Ro60 antigens
    • Anti-La SSB-IgG Antibodies: Target La/SSB antigens exclusively found in salivary gland tissue and lacrimal glands; more specific indicator of primary Sjogren's syndrome affecting glandular epithelial cells
    • Salivary glands: Major and minor salivary glands undergo lymphocytic infiltration and atrophy, resulting in xerostomia (dry mouth), difficulty swallowing, and increased dental caries
    • Lacrimal glands: Destruction leads to xerophthalmia (dry eyes), keratoconjunctivitis sicca, eye discomfort, and visual impairment; corneal involvement may lead to scarring
    • Extraglandular manifestations may involve lungs (interstitial lung disease, bronchiolitis obliterans organizing pneumonia), kidneys (tubulointerstitial nephritis), and nervous system (peripheral neuropathy)
    • Systemic complications associated with Anti-Ro SSA-IgG and Anti-La SSB-IgG positivity include vasculitis, lymphoma risk (up to 43 times higher than general population), and increased cardiovascular complications
    • Gastrointestinal tract: Reduced saliva production affects digestion and increases risk of esophageal candidiasis and gastroesophageal reflux disease
    • Mucous membranes: Reduced mucus production in upper respiratory tract increases susceptibility to infections; vaginal dryness may occur in women
  • Follow-up Tests
    • Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (Anti-CCP): Recommended to exclude or evaluate concurrent rheumatoid arthritis in patients with positive Sjogren's markers
    • Antinuclear Antibody (ANA) panel: Essential screening test as 40-60% of Sjogren's patients are ANA positive; helps identify overlap syndromes with SLE or other connective tissue diseases
    • Schirmer's test: Objective measurement of tear production; abnormal results (<5mm in 5 minutes) support diagnosis and assess severity of lacrimal gland dysfunction
    • Ocular staining tests (Rose Bengal or Lissamine Green): Evaluate corneal and conjunctival damage from xerophthalmia; Van Bijsterveld score assessment provides disease severity grading
    • Unstimulated whole saliva flow rate: Measurement of baseline saliva production; <1.5 mL/15 minutes is diagnostic criterion for Sjogren's syndrome
    • Minor salivary gland biopsy: Gold standard diagnostic test; focus score of >1 focus per 4mm² is consistent with Sjogren's syndrome diagnosis
    • Complete metabolic panel and liver function tests: Screen for extraglandular manifestations and assess baseline organ function before initiating treatment
    • Comprehensive metabolic panel including creatinine and urinalysis: Evaluate for tubulointerstitial nephritis, a known extraglandular manifestation
    • High-resolution CT chest: Recommended at baseline if Anti-Ro/La positive, with follow-up imaging if pulmonary symptoms develop, given increased risk of interstitial lung disease
    • Immunoglobulin levels (IgG, IgA, IgM): Evaluate for hypergammaglobulinemia, common in Sjogren's syndrome and associated with worse prognosis
    • Repeat antibody testing: May be performed annually or as clinically indicated to monitor disease activity; however, antibody titers remain relatively stable over time in most patients
    • Peripheral blood lymphocyte count: Monitor for lymphopenia and assess for systemic involvement; baseline and periodic monitoring recommended
  • Fasting Required?
    • No fasting is required for the Sjogren's Syndrome Profile (Anti-Ro SSA-IgG and Anti-La SSB-IgG antibody testing)
    • These are serology tests measuring antibody levels that are not affected by dietary intake or fasting status
    • Patient can eat and drink normally before blood draw; no dietary restrictions are necessary
    • No specific medications need to be held or avoided prior to testing; however, inform healthcare provider of all current medications as some immunosuppressive agents may affect antibody levels
    • Blood draw can be performed at any time of day; morning or afternoon collection timing does not affect results
    • Standard venipuncture protocol applies: patient should remain seated for 5 minutes prior to collection; arm should be relaxed and extended
    • If Schirmer's test or minor salivary gland biopsy are planned as follow-up testing, coordinate timing as these procedures may be performed on same day or on separate occasions per clinical protocol
    • If concurrent testing with lipid panel or glucose is planned, separate fasting requirements for those tests should be followed; coordinate with ordering healthcare provider

How our test process works!

customers
customers